FR2002888A1 - - Google Patents

Info

Publication number
FR2002888A1
FR2002888A1 FR6905076A FR6905076A FR2002888A1 FR 2002888 A1 FR2002888 A1 FR 2002888A1 FR 6905076 A FR6905076 A FR 6905076A FR 6905076 A FR6905076 A FR 6905076A FR 2002888 A1 FR2002888 A1 FR 2002888A1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR6905076A
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Pharmaceutical Co filed Critical Warner Lambert Pharmaceutical Co
Publication of FR2002888A1 publication Critical patent/FR2002888A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR6905076A 1968-02-29 1969-02-27 Withdrawn FR2002888A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70918068A 1968-02-29 1968-02-29
US78810168A 1968-12-30 1968-12-30

Publications (1)

Publication Number Publication Date
FR2002888A1 true FR2002888A1 (en) 1969-10-31

Family

ID=27108212

Family Applications (1)

Application Number Title Priority Date Filing Date
FR6905076A Withdrawn FR2002888A1 (en) 1968-02-29 1969-02-27

Country Status (3)

Country Link
DE (1) DE1908548A1 (en)
FR (1) FR2002888A1 (en)
GB (1) GB1237059A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2181708A1 (en) * 1972-02-09 1973-12-07 Philips Nv
FR2509728A1 (en) * 1981-07-17 1983-01-21 Roussel Uclaf NOVEL QUINOLINE DERIVATIVES, THEIR SALTS, PREPARATION METHOD, MEDICAMENT APPLICATION AND COMPOSITIONS COMPRISING THE SAME
EP0895776A2 (en) * 1997-08-05 1999-02-10 F. Hoffmann-La Roche Ag Cosmetic light-screening composition
US8829204B2 (en) 2004-06-24 2014-09-09 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9139530B2 (en) 2005-12-28 2015-09-22 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US9751839B2 (en) 2009-03-20 2017-09-05 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US10272046B2 (en) 2012-02-27 2019-04-30 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US10646481B2 (en) 2008-08-13 2020-05-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011073A1 (en) 1996-09-10 1998-03-19 Pharmacia & Upjohn Company 8-hydroxy-7-substituted quinolines as anti-viral agents
PL341364A1 (en) * 1997-12-22 2001-04-09 Upjohn Co 4-hydroxyqinoline-3-carboxamides and hydrazides as antiviral agents
KR102135116B1 (en) * 2018-12-11 2020-07-17 재단법인 경기도경제과학진흥원 Antiviral Composition for Middle East Respiratory Syndrome Coronavirus Using Chloroxine or Analogues Thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1070223A (en) * 1965-03-09 1967-06-01 Ici Ltd Quinoline derivatives
GB1122323A (en) * 1966-08-04 1968-08-07 Ici Ltd Quinoline derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1070223A (en) * 1965-03-09 1967-06-01 Ici Ltd Quinoline derivatives
GB1122323A (en) * 1966-08-04 1968-08-07 Ici Ltd Quinoline derivatives

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2181708A1 (en) * 1972-02-09 1973-12-07 Philips Nv
FR2509728A1 (en) * 1981-07-17 1983-01-21 Roussel Uclaf NOVEL QUINOLINE DERIVATIVES, THEIR SALTS, PREPARATION METHOD, MEDICAMENT APPLICATION AND COMPOSITIONS COMPRISING THE SAME
EP0070767A1 (en) * 1981-07-17 1983-01-26 Roussel-Uclaf Quinoline derivatives, their salts, their preparation, their use as medicines and compositions containing them
EP0895776A2 (en) * 1997-08-05 1999-02-10 F. Hoffmann-La Roche Ag Cosmetic light-screening composition
EP0895776A3 (en) * 1997-08-05 1999-04-28 F. Hoffmann-La Roche Ag Cosmetic light-screening composition
US10662192B2 (en) 2004-06-24 2020-05-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9090619B2 (en) 2004-06-24 2015-07-28 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8829204B2 (en) 2004-06-24 2014-09-09 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US11291662B2 (en) 2005-12-28 2022-04-05 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9139530B2 (en) 2005-12-28 2015-09-22 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9670163B2 (en) 2005-12-28 2017-06-06 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9931334B2 (en) 2005-12-28 2018-04-03 Vertex Pharmaceuticals Incorporated Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US10537565B2 (en) 2005-12-28 2020-01-21 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US11564916B2 (en) 2008-08-13 2023-01-31 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US10646481B2 (en) 2008-08-13 2020-05-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US9751839B2 (en) 2009-03-20 2017-09-05 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US10272046B2 (en) 2012-02-27 2019-04-30 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11147770B2 (en) 2012-02-27 2021-10-19 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11752106B2 (en) 2012-02-27 2023-09-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator

Also Published As

Publication number Publication date
GB1237059A (en) 1971-06-30
DE1908548A1 (en) 1970-11-05

Similar Documents

Publication Publication Date Title
AU1946070A (en)
AU428130B2 (en)
AU2374870A (en)
FR2002888A1 (en)
AU6168869A (en)
AU6171569A (en)
AU416157B2 (en)
AU429879B2 (en)
AU2581067A (en)
AU4811568A (en)
AU421558B1 (en)
AU2580267A (en)
AU3224368A (en)
AR203075Q (en)
AU3789668A (en)
AU463027A (en)
AU2496167A (en)
AU4224469A (en)
AU4464266A (en)
AU4503667A (en)
AU4558658A (en)
BE726225A (en)
AU3083868A (en)
AU479393A (en)
AU2889368A (en)

Legal Events

Date Code Title Description
ST Notification of lapse